CPIs are monoclonal antibodies, which are designed to block ICRs on the surface of exhausted CD8+ T cells, releasing them thus from chronic inhibition, and restoring anti-tumor functionality [23] (Figure 2A). The gene discussed is CD8A; the disease is neoplasm.